| Olanzapine |
II-10316/22,07,2010 |
EGOLANZA, Film coated tablet, 5, mg, Pack: 28 |
EGIS Pharmaceuticals PLC, Унгария |
EGIS Pharmaceuticals PLC, Унгария |
64.54 |
12.91 |
77.45 |
4% |
2.58 |
67.12 |
13.42 |
80.54 |
16% |
10.33 |
77.45 |
15.49 |
92.94 |
|
КЦ-1819/11.10.2010 |
14.12.2010 |
14.12.2010 |
Неактивен |
1893 |
| Olanzapine |
II-10318/22,07,2010 |
EGOLANZA, Film coated tablet, 10, mg, Pack: 28 |
EGIS Pharmaceuticals PLC, Унгария |
EGIS Pharmaceuticals PLC, Унгария |
129.08 |
25.82 |
154.9 |
4% |
5.16 |
134.24 |
26.85 |
161.09 |
16% |
20.65 |
154.89 |
30.98 |
185.87 |
|
КЦ-1819/11.10.2010 |
14.12.2010 |
14.12.2010 |
Неактивен |
1892 |
| Idursulfase |
EU/01/06/365/002 |
Elaprase, Concentrate for solution for infusion, 2 mg/ml – 3 ml, mg, Pack: 4 |
Shire Human Genetic Therapies AB, Швеция |
Shire Human Genetic Therapies AB Sweden |
22883.21 |
4576.64 |
27459.85 |
4% |
10 |
22893.21 |
4578.64 |
27471.85 |
16% |
25 |
22918.21 |
4583.64 |
27501.85 |
Прот. № 137/01.10.2015 |
КЦРР-1345/30.08.2012; НСР-19175/08.07.2019 предварително изпълнение; КП-80/10.10.2019 |
30.08.2012 |
02.11.2019 |
Активен |
1330 |
| Idursulfase |
EU/01/06/365/002 |
Elaprase, Concentrate for solution for infusion, 2 mg/ml – 3 ml, mg, Pack: 4 |
Shire Human Genetic Therapies AB, Швеция |
Shire Human Genetic Therapies AB Sweden |
19626.17 |
3925.23 |
23551.4 |
4% |
10 |
19636.17 |
3927.23 |
23563.4 |
16% |
25 |
19661.17 |
3932.23 |
23593.4 |
Прот. № 137/01.10.2015 |
КЦРР-1345/30.08.2012; НСР-19175/08.07.2019 предварително изпълнение* |
08.07.2019 |
02.08.2019 |
Неактивен |
1330 |
| Idursulfase |
EU/01/06/365/002 |
Elaprase, Concentrate for solution for infusion, 2 mg/ml – 3 ml, mg, Pack: 4 |
Shire Human Genetic Therapies AB, Швеция |
Shire Human Genetic Therapies AB Sweden |
22883.21 |
4576.64 |
27459.85 |
4% |
10 |
22893.21 |
4578.64 |
27471.85 |
16% |
25 |
22918.21 |
4583.64 |
27501.85 |
Прот. № 137/01.10.2015 |
КЦРР-1345/30.08.2012 |
30.08.2012 |
30.08.2012 |
Неактивен |
1330 |
| Idursulfase |
EU/01/06/365/002 |
Elaprase, Concentrate for solution for infusion, 2 mg/ml – 3 ml, mg, Pack: 4 |
Shire Human Genetic Therapies AB, Швеция |
Shire Human Genetic Therapies AB Sweden |
22883.21 |
4576.64 |
27459.85 |
4% |
10 |
22893.21 |
4578.64 |
27471.85 |
16% |
25 |
22918.21 |
4583.64 |
27501.85 |
Прот. № 137/01.10.2015 |
КЦРР-1345/30.08.2012 |
30.08.2012 |
30.08.2012 |
Неактивен |
1330 |
| Idursulfase |
EU/01/06/ 365//001 |
Elaprase, Concentrate for solution for infusion, 2 mg/ml – 3 ml, mg, Pack: 1 |
Shire Human Genetic Therapies AB, Швеция |
Shire HumanGeneric Therapies AB Sweeden |
5112.01 |
1022.4 |
6134.41 |
4% |
10 |
5122.01 |
1024.4 |
6146.41 |
16% |
25 |
5147.01 |
1029.4 |
6176.41 |
цената е заличена с решение КЦРР-1346/30.08.2012 |
КЦРР-587/11.05.2012 |
27.05.2012 |
27.05.2012 |
Заличен |
1212 |
| Enalapril, Lercanidipine |
20130350 |
Elernap, Film coated tablet, 10 mg/10 mg, mg, Pack: 30 |
KRKA, d.d., Словения |
KRKA d.d., Novo mesto, Словения |
11.46 |
2.29 |
13.75 |
6% |
0.69 |
12.15 |
2.43 |
14.58 |
18% |
2.06 |
14.21 |
2.84 |
17.05 |
Цената се вписва в регистъра на пределните цени с решение НСР-6361/03.06.2015( в сила от 02.07.2015) |
НСР-2979/12.03.2014 |
27.03.2014 |
27.03.2014 |
Заличен |
2571 |
| Enalapril, Lercanidipine |
20130351 |
Elernap, Film coated tablet, 20 mg/10 mg, mg, Pack: 30 |
KRKA, d.d., Словения |
KRKA d.d., Novo mesto, Словения |
12.07 |
2.41 |
14.48 |
6% |
0.72 |
12.79 |
2.56 |
15.35 |
18% |
2.17 |
14.96 |
2.99 |
17.95 |
Цената се вписва в регистъра на пределните цени с решение НСР-6360/03.06.2015( в сила от 02.07.2015) |
НСР-2979/12.03.2014 |
27.03.2014 |
27.03.2014 |
Заличен |
2572 |
| Escitalopram |
20090435 |
Elicea, Film coated tablet, 10, mg, Pack: 28 |
KRKA, d.d., Словения |
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Словения |
3.99 |
0.8 |
4.79 |
7% |
0.28 |
4.27 |
0.85 |
5.12 |
20% |
0.8 |
5.07 |
1.01 |
6.08 |
|
НСР-6688/09.07.2015; НСР-13596/25.08.2017; НСР-17116/01.11.2018 |
16.11.2018 |
02.12.2018 |
Активен |
4031 |
| Escitalopram |
20090435 |
Elicea, Film coated tablet, 10, mg, Pack: 28 |
KRKA, d.d., Словения |
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Словения |
6.2 |
1.24 |
7.44 |
7% |
0.43 |
6.63 |
1.33 |
7.96 |
20% |
1.24 |
7.87 |
1.57 |
9.44 |
|
НСР-6688/09.07.2015; НСР-13596/25.08.2017 |
09.09.2017 |
02.10.2017 |
Неактивен |
4031 |
| Escitalopram |
20090436 |
Elicea, Film coated tablet, 20, mg, Pack: 28 |
KRKA, d.d., Словения |
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Словения |
9.31 |
1.86 |
11.17 |
7% |
0.65 |
9.96 |
1.99 |
11.95 |
20% |
1.86 |
11.82 |
2.36 |
14.18 |
|
НСР-6688/09.07.2015; HCP-10163/31.08.2016; НСР-14454/17.11.2017 |
02.12.2017 |
02.01.2018 |
Активен |
4032 |
| Escitalopram |
20090436 |
Elicea, Film coated tablet, 20, mg, Pack: 28 |
KRKA, d.d., Словения |
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Словения |
10.15 |
2.03 |
12.18 |
6% |
0.61 |
10.76 |
2.15 |
12.91 |
18% |
1.83 |
12.59 |
2.52 |
15.11 |
|
НСР-6688/09.07.2015; HCP-10163/31.08.2016 |
16.09.2016 |
02.10.2016 |
Неактивен |
4032 |
| Escitalopram |
20090435 |
Elicea, Film coated tablet, 10, mg, Pack: 28 |
KRKA, d.d., Словения |
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Словения |
6.28 |
1.26 |
7.54 |
7% |
0.44 |
6.72 |
1.34 |
8.06 |
20% |
1.26 |
7.98 |
1.6 |
9.58 |
|
НСР-6688/09.07.2015 |
25.07.2015 |
25.07.2015 |
Неактивен |
4031 |
| Escitalopram |
20090436 |
Elicea, Film coated tablet, 20, mg, Pack: 28 |
KRKA, d.d., Словения |
KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Словения |
13.1 |
2.62 |
15.72 |
6% |
0.79 |
13.89 |
2.78 |
16.67 |
18% |
2.36 |
16.25 |
3.25 |
19.5 |
|
НСР-6688/09.07.2015 |
25.07.2015 |
25.07.2015 |
Неактивен |
4032 |
| Venlafaxine |
20080092 |
Elify XR, prolonged‐release capsule, hard, 150, mg, Pack: 30 |
Medochemie Ltd., Кипър |
Medochemie Ltd., Cyprus |
12.58 |
2.52 |
15.1 |
6% |
0.75 |
13.33 |
2.67 |
16 |
18% |
2.26 |
15.59 |
3.12 |
18.71 |
Цената се заличава с решение НСР-3149/26.03.2014 |
HCР-521/11.07.2013. |
29.07.2013 |
29.07.2013 |
Заличен |
1972 |
| Venlafaxine |
II-2248/ 11.06.2008 |
Elify XR, prolonged‐release capsule, hard, 150, mg, Pack: 30 |
Medochemie Ltd., Кипър |
Medochemie Ltd, Cyprus |
31.8 |
6.36 |
38.16 |
4% |
1.27 |
33.07 |
6.61 |
39.68 |
16% |
5.09 |
38.16 |
7.63 |
45.79 |
|
КЦРР-210/27.02.2012 |
20.03.2012 |
20.03.2012 |
Неактивен |
1972 |
| Venlafaxine |
II-2248/11.06.2008 |
Elify XR, prolonged‐release capsule, hard, 150, mg, Pack: 30 |
Medochemie Ltd., Кипър |
Medochemie Ltd, Cyprus |
42.25 |
8.45 |
50.7 |
6% |
2.54 |
44.79 |
8.96 |
53.75 |
18% |
7.61 |
52.4 |
10.48 |
62.88 |
|
КЦ-494/04.02.2009 |
24.02.2009 |
24.02.2009 |
Неактивен |
1972 |
| Venlafaxine |
20080091 |
ELIFY XR, Prolonged release capsule, hard, 75, mg, Pack: 30 |
Medochemie Ltd., Кипър |
Medochemie Ltd., Cyprus |
5.32 |
1.06 |
6.38 |
7% |
0.37 |
5.69 |
1.14 |
6.83 |
20% |
1.06 |
6.75 |
1.35 |
8.1 |
Корекционно решение НСР-18621/25.04.2019 |
HCР-7710/17.12.2015; НСР-18287/28.03.2019 |
12.04.2019 |
02.06.2019 |
Активен |
1971 |
| Venlafaxine |
20080091 |
ELIFY XR, Prolonged release capsule, hard, 75, mg, Pack: 30 |
Medochemie Ltd., Кипър |
Medochemie Ltd., Cyprus |
5.32 |
1.06 |
6.38 |
7% |
0.37 |
5.69 |
1.14 |
6.83 |
20% |
1.06 |
6.75 |
1.35 |
8.1 |
|
HCР-7710/17.12.2015; НСР-18287/28.03.2019 |
12.04.2019 |
02.05.2019 |
Неактивен |
1971 |
| Venlafaxine |
20080091 |
ELIFY XR, Prolonged release capsule, hard, 75, mg, Pack: 30 |
Medochemie Ltd., Кипър |
Medochemie Ltd., Cyprus |
6.45 |
1.29 |
7.74 |
7% |
0.45 |
6.9 |
1.38 |
8.28 |
20% |
1.29 |
8.19 |
1.64 |
9.83 |
|
HCР-7710/17.12.2015 |
02.01.2016 |
02.01.2016 |
Неактивен |
1971 |
| Venlafaxine |
20080091 |
ELIFY XR, Prolonged release capsule, hard, 75, mg, Pack: 30 |
Medochemie Ltd., Кипър |
Medochemie Ltd., Cyprus |
7.63 |
1.53 |
9.16 |
7% |
0.53 |
8.16 |
1.63 |
9.79 |
20% |
1.53 |
9.69 |
1.94 |
11.63 |
|
HCР-522/11.07.2013. |
29.07.2013 |
29.07.2013 |
Неактивен |
1971 |
| Venlafaxine |
II-2247/ 11.06.2008 |
ELIFY XR, Prolonged release capsule, hard, 75, mg, Pack: 30 |
Medochemie Ltd., Кипър |
Medochemie Ltd, Cyprus |
15.69 |
3.14 |
18.83 |
6% |
0.94 |
16.63 |
3.33 |
19.96 |
18% |
2.82 |
19.45 |
3.89 |
23.34 |
|
КЦРР-210/27.02.2012 |
20.03.2012 |
20.03.2012 |
Неактивен |
1971 |
| Venlafaxine |
II-2247/11.06.2008 |
ELIFY XR, Prolonged release capsule, hard, 75, mg, Pack: 30 |
Medochemie Ltd., Кипър |
Medochemie Ltd, Cyprus |
21.32 |
4.26 |
25.58 |
8% |
1.71 |
23.03 |
4.61 |
27.64 |
20% |
4.26 |
27.29 |
5.46 |
32.75 |
|
КЦ-494/04.02.2009 |
24.02.2009 |
24.02.2009 |
Неактивен |
1971 |
| Leuprorelin |
20070097 |
ELIGARD, Powder and solvent for solution for injection, 45, mg, Pack: 1 |
Astellas Pharma d.o.o, Словения |
Astellas Pharma Europe B.V., The Netherlands |
538.19 |
107.64 |
645.83 |
4% |
10 |
548.19 |
109.64 |
657.83 |
16% |
25 |
573.19 |
114.64 |
687.83 |
Корекционно решение НСР-16848/20.09.2018 |
НСР-6144/29.04.2015.; НСР-9624/23.06.2016г.; НСР-12144/27.03.2017 г.; НСР-14905/25.01.2018; НСР-17239/12.11.2018 предварително изпълнение; НСР-19369/26.07.2019 предварително изпълнение |
26.07.2019 |
02.09.2019 |
Активен |
3859 |